Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988115 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT02988115 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 345 participants.
The verdict
NCT02988115, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Interventions
- OTHER placebo
- DRUG bempedoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2018-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988115
The ClinicalTrials.gov registry entry for NCT02988115 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02988115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02988115 about?
NCT02988115 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant". The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
What is the current status of trial NCT02988115?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2016-11-16. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT02988115?
The interventions under investigation include: placebo (OTHER), bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT02988115?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.